Cadrenal Therapeutics (CVKD) Operating Leases (2022 - 2023)

Cadrenal Therapeutics (CVKD) posted Operating Leases of $2232.0 for Q3 2023, down 74.62% sequentially from $8796.0 in Q2 2023.

Cadrenal Therapeutics (CVKD) Operating Leases (2022 - 2023) Analysis & Trends

Cadrenal Therapeutics has reported Operating Leases for 2 years, with the latest figure at $2232.0 in Q3 2023.

Quarterly Operating Leases changed N/A year-over-year to $2232.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $2232.0 (changed N/A YoY) and the FY2022 annual result came in at $21350.0, changed N/A from the prior year.
Operating Leases retreated to $2232.0 in Q3 2023 per CVKD's latest filing, from $8796.0 in the prior quarter.
Over five years, Operating Leases peaked at $38329.0 in Q1 2023 and troughed at $2232.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cadrenal Therapeutics	4.59 Mn	2.19 Mn	-

Download Data